NCT02229877View on ClinicalTrials.gov

A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 6, 2014

Primary Completion Date

May 14, 2015

Study Completion Date

May 22, 2015

Conditions
Healthy Volunteers
Interventions
DRUG

Omeprazole

40 mg oral capsules administered twice daily for 8.5 days

DRUG

Gefapixant

Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days

DRUG

Gefapixant

Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days

DRUG

Gefapixant

Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days

Sponsors

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY